Printer Friendly

ARBUTAMINE PHASE 2 CLINICAL DATA ABSTRACT PUBLISHED IN JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY

 ARBUTAMINE PHASE 2 CLINICAL DATA ABSTRACT PUBLISHED
 IN JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY
 SAN DIEGO, June 9 /PRNewswire/ -- Gensia Pharmaceuticals Inc. (NASDAQ: GNSA) today announced that an abstract summarizing data from 30 patients participating in a U.S. multicenter Phase 2 human clinical trial with arbutamine (a drug which is part of the GenESA(TM) System) indicated that arbutamine appeared to be as effective as physical exercise in diagnosing coronary artery disease when used with echocardiography (ultrasound imaging of the heart). The abstract was published in the June 1992 issue of the Journal of the American Society of Echocardiography.
 Each patient was tested twice in random order, once using physical exercise stress and once with arbutamine stress. The drug was administered intravenously by a physician. Coronary artery disease was detected in 27 of 30 patients with exercise echocardiography (90 percent) and in 29 of 30 patients with arbutamine stress echocardiography (97 percent). Cardiac ischemia (lack of oxygenated blood flow to the heart often due to blockages in the coronary arteries) was induced in 23 patients with exercise (77 percent) and in 27 patients with arbutamine (90 percent). The detection of cardiac ischemia is important in that it normally indicates evolving or worsening coronary artery disease. All patients enrolled had confirmed coronary artery disease.
 In this study, arbutamine appeared to be as effective as exercise in provoking ischemia in patients with coronary artery disease who were able to exercise adequately. Arbutamine, but not exercise, induced ischemia in a small number of patients unable to achieve an adequate level of exercise. All patients successfully completed the study protocol with no serious adverse effects.
 The abstract is scheduled to be presented by researchers from the University of Michigan at the Annual Scientific Meeting of the American Society of Echocardiography in Boston on June 15.
 In order to diagnose coronary artery disease, in most patients it is usually necessary to stress the heart, typically with physical exercise. If blockages exist in the coronary arteries, they will prevent the required flow of blood during stress, resulting in ischemia and cardiac dysfunction. Depending on the severity of the dysfunction, it can usually be detected by electrocardiography (ECG), echocardiography or radionuclide imaging.
 The GenESA System combines the drug, arbutamine, and a computer- controlled drug administration system designed to pharmacologically stress the heart to aid in the diagnosis of coronary artery disease. The GenESA System is currently being tested in multicenter Phase 3 clinical trials with ECG, echocardiography and radionuclide imaging both in patients who are able and patients unable to exercise.
 The company believes that a primary clinical need for the GenESA System is for use with patients who are unable to undergo exercise stress tests or who have had inconclusive exercise stress ECG tests. In addition, the GenESA System is also expected to enhance echocardiography, which is the fastest growing cardiac test worldwide, and radionuclide imaging procedures, which are difficult to perform in conjunction with physical exercise.
 The company estimates that in the United States, as many as 1.5 million patients who are candidates for testing for coronary artery disease are unable to exercise adequately due to physical disabilities or limitations. In addition, of the 6 million exercise stress ECGs performed each year in the United States, an estimated 20 percent to 30 percent of tests are inconclusive, frequently because the patient is unable to achieve a sufficient increase in heart rate for diagnosis of coronary artery disease to be made. There are approximately 6 million echocardiography and 1.5 million radionuclide imaging procedures performed each year in the United States.
 Gensia Clinical Partners owns certain rights to the GenESA System technology which are subject to a purchase option by Gensia.
 Gensia Pharmaceuticals is a San Diego-based biopharmaceuticaliseases.
 -0- 6/9/92
 /CONTACT: Martha L. Hough or Elizabeth A. Gard of Gensia Pharmaceuticals, 619-546-8300/
 (GNSA) CO: Gensia Pharmaceuticals Inc. ST: California IN: MTC SU:


KJ-EH -- SD001 -- 8213 06/09/92 08:34 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 9, 1992
Words:660
Previous Article:HOMEDCO GROUP ISSUES STATEMENT REGARDING RECENT ACTIVITY IN THE MARKET FOR ITS STOCK
Next Article:NORTH AMERICAN BIOLOGICALS INCREASES PLASMA COLLECTION CAPABILITIES
Topics:


Related Articles
ARASINE PHASE 2 CLINICAL ABSTRACT IN BYPASS SURGERY PUBLISHED IN JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
ARBUTAMINE CLINICAL AND PRECLINICAL DATA ABSTRACTS PUBLISHED IN CIRCULATION
GENSIA FILES NDA FOR ARASINE AS PLANNED WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA)
DATA ON ARBUTAMINE PRESENTED AT ACC
ARBUTAMINE PHASE 3 CLINICAL ABSTRACTS PUBLISHED IN JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
GENSIA ANNOUNCES CPMP RECOMMENDATION FOR APPROVAL OF GenESA(R) SYSTEM IN EUROPE
GENSIA RECEIVES PATENT ON GenESA(R) SYSTEM DRUG
AltaRex Publishes Early Prospective OvaRex(TM) MAb Data in the Journal Blood And Announces Updated Results.
YM BioSciences announces appointment of Dr. Daniel D. Von Hoff to its Advisory Board.
NeoPharm and collaborators unveil cancer study results.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters